Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIK-333 Phase 2/3 Study in HCV-positive Hepatocellular Carcinoma
jRCT2080220246Phase 3
- Sponsor
- Kowa Company, Ltd.
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of peretinoin in hepatocellular carcinoma (HCC) and hepatitis C virus infection (3 arms), sponsored by Kowa Company, Ltd.
02
Drugs
peretinoin
03
Conditions
hepatocellular carcinoma (HCC)hepatitis C virus infection
Beyond the preview
Go deeper on jRCT2080220246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220246.